Matsumura Shuichi, Nakamori Mikihito, Tsuji Toshiaki, Kato Tomoya, Nakamura Masaki, Ojima Toshiyasu, Fukuhara Hiroshi, Ino Yasushi, Todo Tomoki, Yamaue Hiroki
Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
Division of Digestive Surgery, Osaka Minami Medical Center, National Hospital Organization, Kawachinagano, Osaka, Japan.
Oncotarget. 2021 Feb 16;12(4):344-354. doi: 10.18632/oncotarget.27873.
Oncolytic virotherapy is an encouraging treatment using herpes simplex virus (HSV) for gastric cancer patients. To treat gastric cancer, we generated and evaluated the efficacy of an attractive type of oncolytic HSV expressing the suppressor of cytokine signaling 3 (SOCS3). We constructed a third-generation type of oncolytic HSV (T-SOCS3) arming with SOCS3 by a bacterial artificial chromosome (BAC) system. We examined the viral replicative intensification and oncolysis of T-SOCS3 for human gastric cancer cell lines . T-SOCS3 enhanced its replication and potentiated its cell-killing effect for MKN1 human gastric cancer cell lines, which are resistant to a non-armed third-generation type of oncolytic HSV (T-01) . T-SOCS3 also induced the destruction within human gastric cancer specimens. Armed oncolytic HSVs expressing SOCS3 may be an efficacious therapeutic agent for gastric cancer treatment.
溶瘤病毒疗法是一种令人鼓舞的治疗方法，即使用单纯疱疹病毒（HSV）治疗胃癌患者。为了治疗胃癌，我们构建并评估了一种表达细胞因子信号传导抑制因子3（SOCS3）的溶瘤HSV的疗效。我们通过细菌人工染色体（BAC）系统构建了携带SOCS3的第三代溶瘤HSV（T-SOCS3）。我们检测了T-SOCS3对人胃癌细胞系的病毒复制增强和溶瘤作用。T-SOCS3增强了其在对非携带第三代溶瘤HSV（T-01）耐药的MKN1人胃癌细胞系中的复制，并增强了其细胞杀伤作用。T-SOCS3还诱导了人胃癌标本内的破坏。表达SOCS3的携带溶瘤HSV可能是一种有效的胃癌治疗药物。
